This activity is a video-based program in which 2 experts discuss the etiology of atherosclerotic cardiovascular disease (ASCVD) and the management of hyperlipidemia to reduce risk. Expert faculty focus on the role of elevated lipids in the development of ASCVD...

Research revealing that overexpression of TL1A drives key pathological pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in...